<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02202213</url>
  </required_header>
  <id_info>
    <org_study_id>15698A</org_study_id>
    <nct_id>NCT02202213</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability Study of Lu AF11167 After Repeated Dosing in Patients With Schizophrenia</brief_title>
  <official_title>Interventional, Randomised, Double-blind, Placebo Controlled, Multiple-dose Study Investigating the Safety, Tolerability, PK and PD Properties of Lu AF11167 in Patients With Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lundbeck A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability of Lu AF11167 in
      patients with schizophrenia following various repeated dosing regimens of Lu AF11167 (alone
      or as added treatment to risperidone).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute values and changes from baseline in safety variables (Adverse events, clinical safety laboratory tests, vital signs,respiratory rate, weight, body temperature and ECG)</measure>
    <time_frame>Screnning to day 25</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Columbia Suicide Severity Rating Scale (C-SSRS)</measure>
    <time_frame>Screening to day 25</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Lu AF11167 hard capsules; 0.25, 0.5 and 1 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A: Lu AF11167 monotherapy Part B: Lu AF11167 adjunctive therapy to risperidone
Three times daily oral dosing for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Daily oral dosing matching the experimental arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Matching placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lu AF11167</intervention_name>
    <arm_group_label>Lu AF11167 hard capsules; 0.25, 0.5 and 1 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Man or woman aged ≥18 years and ≤60 years with a body mass index (BMI) of ≥18.5 and
             ≤38 m2

          -  Primary diagnosis of schizophrenia according to DSM-IV-TR™ (codes 295.10, 295.20,
             295.30, 295.90)

          -  Clinical Global Impression - Severity of Illness (CGI-S) score ≤4 (moderately ill) at
             the Screening Visit and Baseline Visit (Day -1)

          -  PANSS total score ≤80 at the Screening Visit and the Baseline Visit (Day -1)

          -  Score of 4 (moderate) of the following PANSS items at the Screening Visit and the
             Baseline Visit (Day -1): P7 (hostility), G8 (uncooperativeness)

          -  Minimal level of extrapyramidal signs, defined as a score ≤5 (moderately severe) in
             any of the four Clinical Global Impression of Severity (CGI-S) items of the ESRS-A;
             parkinsonism, akathisia, dystonia, and tardive dyskinesia at the Screening Visit and
             the Baseline Visit

          -  Willingness to be hospitalised for approximately 3 weeks after the Baseline Visit (Day
             -1)

        Exclusion Criteria:

          -  The patient experienced an acute exacerbation requiring hospitalization within the
             last 6 months

          -  The patient experienced an acute exacerbation requiring increase in antipsychotic
             medication (with reference to drug or dose) within the last 4 weeks

        Other pre-defined inclusion and exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email contact via H.Lundbeck A/S</last_name>
    <role>Study Director</role>
    <affiliation>LundbeckClinicalTrials.com</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Parexel International</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 25, 2014</study_first_submitted>
  <study_first_submitted_qc>July 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2014</study_first_posted>
  <last_update_submitted>February 17, 2015</last_update_submitted>
  <last_update_submitted_qc>February 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

